Halozyme Therapeutics Inc (HALO) — Cash Flow Reinvestment Rate
Halozyme Therapeutics Inc (HALO) has a Cash Flow Reinvestment Rate of 1.15x as of September 2025, reinvesting $204.64 Million (capex $3.03 Million plus investments $201.61 Million) from operating cash flow of $178.60 Million. See cash generation quality of Halozyme Therapeutics Inc to measure how efficiently the company converts operating cash flow to free cash.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Halozyme Therapeutics Inc Cash Flow Reinvestment Rate (2006–2024)
Historical reinvestment intensity for Halozyme Therapeutics Inc across 7 annual periods. For the full cash flow conversion analysis, see cash efficiency ratio of Halozyme Therapeutics Inc.
Annual Cash Flow Reinvestment Rate for Halozyme Therapeutics Inc (2006–2024)
Year-by-year capital reinvestment analysis for Halozyme Therapeutics Inc. See Halozyme Therapeutics Inc (HALO) financial flexibility to measure the company's free cash flow as a share of total liabilities.
| Year | Reinvestment Rate | Total Reinvested (USD) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2024 | 0.57x | $273.42 Million | $479.06 Million | $10.70 Million | ▲ +97.7% |
| 2023 | 0.29x | $112.20 Million | $388.57 Million | $15.29 Million | ▼ -86.0% |
| 2022 | 2.06x | $495.73 Million | $240.11 Million | $4.81 Million | ▲ +52.2% |
| 2021 | 1.36x | $406.29 Million | $299.44 Million | $1.46 Million | ▼ -8.6% |
| 2020 | 1.48x | $82.29 Million | $55.45 Million | $2.50 Million | ▲ +20.5% |
| 2017 | 1.23x | $165.08 Million | $134.05 Million | $1.35 Million | ▲ +2289.9% |
| 2006 | 0.05x | $364.80K | $7.08 Million | $364.80K | — |